Introduction
============

Ovarian tumor torsion is an acute gynecological condition that requires emergency surgery. Torsion is more likely to occur with benign rather than malignant tumors ^[@B1]-\ [@B3]^. Mature cystic teratoma of the ovary (MCTO) is a benign tumor that is frequently observed in women of reproductive age. However, malignant transformation occurs in \<2% of MCTO ^[@B4]^. Here, we report a woman with malignant transformation of MCTO, which was presented as ovarian tumor torsion, and review the literature.

Case presentation
=================

A 51-year-old premenopausal woman gravida 3, para 3, was diagnosed with left MCTO 7 years ago. The size of the MCTO was 59 mm at the time of diagnosis. She underwent regular ovarian examination for 2 years after the diagnosis but had not visited the hospital for 5 years. She had a history of appendectomy at 7 years of age and received medication for hyperthyroidism since she was 37 years old. She experienced left lower abdominal pain for 2 days and visited the hospital due to increasing pain. Physical examination showed a flat abdomen with tenderness around the left lower abdomen. A solid tumor was palpable by bimanual examination on the left side. Transvaginal ultrasonography revealed a 91-mm cystic and solid ovarian mass on the left ovary ([Fig. 1](#F1){ref-type="fig"}). She was diagnosed with ovarian tumor torsion and had to undergo emergency surgery. Height, weight, and body mass index (BMI) were 165 cm, 96 kg, and 35.3 kg/m ^2^, respectively. Body temperature was within the normal range, pulse rate was 84 beats/min, and blood pressure was 121/55 mmHg. Peripheral blood examination showed that the white blood cell count was 8,820/μL, red blood cell count was 4.65 × 10 ^6^/μL, hemoglobin was 12.1 g/dL, and hematocrit was 37.5%. Biochemical data revealed that the C-reactive protein level was as high as 13.9 mg/dL. Levels of tumor makers, namely serum α-fetoprotein, carbohydrate antigen 19-9 (CA19-9), CA125, and squamous cell carcinoma (SCC) antigen were 4.0 ng/mL (reference, \<10.0 ng/mL), \< 2.0 U/mL (reference, \< 37.0 U/mL), 84.1 U/mL (reference, \< 35.0 U/mL), and 1.4 ng/mL (reference, \< 1.5 ng/mL), respectively. Laparotomy was immediately performed. Operative findings showed 360° torsion of the left ovarian tumor without ascites in the pelvic cavity. There were no sign of congestion and rupture on the surface of the twisted ovary. The uterus and right ovary appeared normal. Left salpingo-oophorectomy was performed. The duration of operation was 54 min, and the volume of blood loss was 30 mL. The diameter of the extirpated ovarian tumor was 11 cm, and the tumor contained fat and hair. Histopathological findings showed both components of mature cystic teratoma and SCC with marked nuclear and cellular atypia in the solid part ([Fig. 2](#F2){ref-type="fig"}). The pathological diagnosis was malignant transformation with SCC of MCTO. We recommended staging laparotomy to determine the treatment strategy. The patient refused to undergo the procedure; subsequently, a strict follow-up for stage IA ovarian cancer was conducted. The patient was discharged from the hospital 10 days post operation. On postoperative day 112, the serum CA125 level was as high as 101.4 U/mL. Positron-emission tomography and computed tomography (CT) showed some nodal lesions with remarkable uptake of 18F-fluorodeoxy glucose ([Fig. 3](#F3){ref-type="fig"}). She was referred to a university hospital due to cancer recurrence. Her BMI was as high as 37.8 kg/m ^2^, and biochemical examination showed that she had hyperlipidemia and diabetes mellitus. The serum CA125, SCC antigen, CA19-9, and carcinoembryonic antigen (CEA) levels were 216 U/mL (reference, \< 35.0 U/mL), 2.0 ng/mL (reference, \< 1.5 ng/mL), \< 2.0 U/mL (reference, \< 37.0 U/mL), and 3.5 ng/mL (reference, \< 5.0 ng/mL), respectively. The patient underwent radical surgery with total abdominal hysterectomy, right salpingo-oophorectomy, partial omentectomy, and pelvic and para-aortic lymph node dissection. Operative findings revealed that there was no ascites or dissemination in the abdominal cavity; no metastatic lesion was found in the uterus and right adnexa. The enlarged pelvic and para-aortic lymph nodes were removed. Thereafter, complete surgical treatment was achieved. The duration of operation was 360 min, and the volume of blood loss was 370 mL. Histopathological examination showed positive lymph nodes with SCC. The numbers of positive/total resected lymph nodes in the left obturator, left external iliac, and para-aortic nodes were 1/5, 2/7, and 1/1, respectively. Immunostaining was performed to assess whether the tumor cells were of epithelial or germ cell origin ([Table 1](#T1){ref-type="table"}); the results confirmed recurrence of the malignant transformation of MCTO with SCC ([Fig. 4](#F4){ref-type="fig"}). The postoperative course was uneventful, and the patient was discharged 10 days post-op. She received 6 courses of conventional paclitaxel and carboplatin as adjuvant chemotherapy. She has had no recurrence for 2 years after treatment. The treatment course is shown in [Fig. 5](#F5){ref-type="fig"}.

![Transvaginal ultrasonographic findings at onset of ovarian torsion\
Transvaginal ultrasonography revealed a 91-mm cystic and solid ovarian mass on the left adnexal lesion.](2185-4610-66-044-g001){#F1}

![Histopathological findings of the left adnexal tumor at the time of initial surgery\
A. Macroscopic appearance of the left ovarian tumor. The arrow indicates the left fallopian tube. B. Histological findings of mature cystic teratoma with keratinized epidermis and sebaceous glands (part of "a" of photograph A). C and D. Histological findings of squamous cell carcinoma component showing honeycomb-like arrangement with severe nuclear atypia (C, low magnification; D, high magnification).](2185-4610-66-044-g002){#F2}

![PET-CT images\
A, B. High accumulation of FDG in the para-aortic lesion (SUVmax = 18.3). A, coronal section; B, transverse section. C, D. High accumulation of FDG in pelvic lymph nodes (SUV max = 14.2). C, coronal section; D, transverse section.\
PET, positron-emission tomography ; CT, computed tomography ; FDG, 18F-fluorodeoxyglucose ; SUVmax, maximum standardized uptake value](2185-4610-66-044-g003){#F3}

###### 

Immunostaining expression of various markers in resected lymph nodes

  ------------------- -------------------- ------------------
                      Markers of\          Markers of germ\
                      epithelial origin\   cell origin
                      or others            

  Positive staining   CK AE1/AE3\          none
                      EMA\                 
                      CK5/6\               
                      p63\                 
                      p40\                 
                      Calponin\            
                      BAF47                

  Negative staining   CD30\                c-kit\
                      SMA                  Oct3/4\
                                           SALL4\
                                           AFP\
                                           hCG
  ------------------- -------------------- ------------------

CK, cytokeratin ; SMA, smooth muscle actin ; AFP, α-fetoprotein ; hCG, human chorionic gonadotropin

![Histopathological findings of resected lymph node\
A, B. Resected para-aortic lymph node shows substantial cellular and nuclear atypia (A, low magnification (40×); B, high magnification (400×).](2185-4610-66-044-g004){#F4}

![Clinical course of treatment\
The solid line indicates the CA125 level. The dotted line indicates the SCC antigen level.\
LSO, left salpingo-oophorectomy; ATH, abdominal hysterectomy; RSO, right salpingo-oophorectomy; PLD, pelvic lymphadenectomy; PAN, para-aortic lymphadenectomy; pOME, partial omentectomy; TC, paclitaxel and carboplatin](2185-4610-66-044-g005){#F5}

Discussion
==========

Ovarian tumor torsion is more likely to occur with benign rather than malignant tumors. The actual incidence of adnexal mass torsion is unknown. Two studies reported that ovarian torsion accounted for 2.7% of emergency surgeries ^[@B5]^ and 15% of adnexal mass surgeries ^[@B6]^. The proportion of torsion with malignant ovarian tumors is approximately 2% ^[@B1]-\ [@B3]^. A higher incidence of malignant tumors in cases of torsion was noted in menopausal women than in premenopausal women ^[@B7],\ [@B8]^. As malignant ovarian tumors are less likely to cause torsion, it is assumed that they adhere to adjacent pelvic tissue. In this case, however, the tumor did not adhere to anything and was twisted. Because MCTO, which is a benign tumor, is thought to be less likely to cause adhesion, the initial stage of malignant transformation of MCTO might be prone to torsion.

Although MCTO is a benign ovarian tumor that represents 20% of all ovarian tumors, it may progress to malignancy ^[@B4]^. The incidence of malignant transformation of MCTO is approximately 0.2-2% ^[@B4],\ [@B9]-\ [@B12]^. SCC, which arises from the ectoderm, accounts for 80% of malignant transformations ^[@B4],\ [@B13]^. Other reported types of malignant transformation of MCTO include basal cell carcinoma, melanoma, adenocarcinoma, thyroid carcinoma, and carcinoid ^[@B4],\ [@B13]^. In this case, it was difficult to distinguish between SCC and germ cell tumors based on tissue morphology. Immunostains for epithelial and germ cell markers yielded a histopathological diagnosis of SCC ([Table 1](#T1){ref-type="table"}). Immunostaining of epithelial markers, such as CK10 and CK18, are useful in the pathological diagnosis of SCC^[@B4]^.

Studies have reported various risk factors for malignant transformation of MCTO^[@B4],\ [@B13]-[@B15]^; including age \> 45 years, tumor diameter \> 10 cm, and high tumor marker levels. As far as tumor markers are concerned, serum SCC antigen levels are frequently high in patients with SCC arising from MCTO^[@B4],[@B13],\ [@B16]-[@B19]^. Levels of other tumor markers, such as serum CA125, C19-9, and CEA, are also high in patients with various histological types of malignant transformation of MCTO ^[@B13],[@B17]^. In this case, the patient had the following risk factors: age \> 45 years, tumor diameter \> 10 cm, and elevated serum CA125.

CT and magnetic resonance imaging (MRI) are useful for the preoperative diagnosis of malignant transformation of MCTO ^[@B4]^. Kido *et al.* reported the MRI findings for malignant transformation of MCTO and revealed that gadolinium enhancement might be helpful in its diagnosis ^[@B20]^. Moreover, Futagami *et al.* reported that gadolinium enhancement of the solid part of the tumor by MRI is a risk factor for malignant transformation ^[@B15]^. In this case, we did not perform CT or MRI because an emergency surgery was performed. Ovarian tumor torsion may affect CT or MR images due to the time lapse after torsion and disruption of blood supply ^[@B21]^. Physicians should consider this point during diagnosis.

Although the incidence of torsion or rupture of MCTO is 0.3-16% ^[@B22],\ [@B23]^, ovarian tumor torsion in malignant transformation of MCTO has not been comprehensively analyzed. Therefore, we searched for cases of malignant transformation of MCTO presenting as ovarian tumor torsion in PubMed and Ichushi databases, the latter being a medical literature service provided by the nonprofit organization Japan Medical Abstracts Society. We searched for keywords, such as "mature cystic teratoma," "malignant transformation," and "ovarian torsion." These keywords were present in seven cases, and there were eight cases including this case of malignant transformation of MCTO with torsion ^[@B24]-\ [@B30]^ ([Table 2](#T2){ref-type="table"}). The age of onset ranged from 38 to 77 years, and five of six patients were menopausal. All eight patients complained of lower abdominal pain and underwent emergency surgery. The laterality of torsion was on the right side in six patients and the left side in two patients. Two of eight patients had MCTO on both sides, and one case had SCC on the side without any torsion. Five of seven patients had increased serum tumor marker levels. The median diameter of the ovarian tumor on the torsion side was 11 cm (range, 7-11 cm). Seven of eight patients underwent laparotomy, and only one patient underwent laparoscopic surgery. Peritoneal cytology was performed in three of eight patients; no patients received rapid pathological diagnosis. The most common pathological diagnosis of malignant lesion was SCC (4 patients). Radical surgery for ovarian cancer was performed in two patients, including ours. Except for our case, among four patients with the same prognosis, no recurrence after treatment has been reported.

###### 

Cases with malignant transformation of mature cystic teratoma of the ovary presenting as ovarian tumor torsion

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors\                 Age   Menopause   Symptoms   Torsion side   Rupture   Ascites       Contralateral ovary   Maximal tumor size (cm)   Elevated tumor marker levels   Initial surgery   Abdominal cytology   Rapid pathology   Pathological diagnosis                 Additional treatments       Staging   Prognosis
  (publication year)                                                                                                                                                                                                                                                                                                
  ------------------------ ----- ----------- ---------- -------------- --------- ------------- --------------------- ------------------------- ------------------------------ ----------------- -------------------- ----------------- -------------------------------------- --------------------------- --------- ---------------------------------
  Okano *et al.*\          77    Yes         LAP, AA    Right          No        Yes, bloody   None of the tumors    13                        None                           BSO\              Yes                  No                MCT with carcinoid                     None                        N.A.      N.A.
  (2002)                                                                                                                                                                      (laparotomy)                                                                                                                          

  Min *et al.*\            77    Yes         LAP, AA    Right          No        Yes, bloody   None of the tumors    17                        CA125                          ATH+BSO\          Yes                  No                MCT with intestinal adenocarcinoma     None                        N.A.      NED at 1 year after surgery
  (2006)                                                                                                                                                                      (laparotomy)                                                                                                                          

  Korkontzelos *et al.*\   56    Yes         LAP, AA    Right          No        N.A.          None of the tumors    17                        N.A.                           ATH+BSO\          No                   No                MCT with SCC                           None                        N.A.      NED at 4 years after surgery
  (2010)                                                                                                                                                                      (laparotomy)                                                                                                                          

  Tamura *et al.*\         55    Yes         LAP, AA    Right          No        N.A.          MCT with SCC          11                        CA19-9, SCC, CEA               BSO\              Yes                  No                MCT with SCC                           ATH+PLD+\                   IA        NED at 3 years after surgery
  (2013)                                                                                                                                                                      (laparotomy)                                                                                    PAN+OME                               

  Nagao *et al.*\          50s   Yes         LAP, AA    Right          No        None          MCT                   8                         hCG, CA19-9                    BSO\              No                   No                MCT with carcinoid                     None                        N.A.      N.A.
  (2015)                                                                                                                                                                      (laparotomy)                                                                                                                          

  Yamada *et al.*\         38    N.A.        LAP, AA    Right          No        None          None of the tumors    7                         SCC                            Cystectomy\       No                   No                MCT with SCC                           None                        N.A.      NED at 1.5 years after surgery
  (2016)                                                                                                                                                                      (laparoscopy)                                                                                                                         

  Cokmez *et al.*\         38    N.A.        LAP, AA    Left           No        N.A.          None of the tumors    11                        None                           BSO\              No                   No                MCT with papillary thyroid carcinoma   None                        N.A.      N.A.
  (2019)                                                                                                                                                                      (laparotomy)                                                                                                                          

  Present case             51    No          LAP, AA    Left           No        None          None of the tumors    11                        CA125, SCC                     LSO\              No                   No                MCT with SCC                           ATH+RSO+\                   IA        NED at 2 years after treatments
                                                                                                                                                                              (laparotomy)                                                                                    PLD+PAN+\                             
                                                                                                                                                                                                                                                                              OME+adjuvant chemotherapy             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ATH, abdominal total hysterectomy ; BSO, bilateral salpingo-oophorectomy ; MCT, mature cystic teratoma ; SCC, squamous cell carcinoma ; PLD, pelvic lymphadenectomy ; PAN, para-aortic lymphadenectomy ; OME, omentectomy ; NED, no evidence of disease ; N.A., not applicable

The standard therapy for malignant transformation of MCTO includes radical surgery and adjuvant chemotherapy according to the staging ^[@B4]^. In patients who choose not to have children, radical surgery, such as bilateral salpingo-oophorectomy, hysterectomy, and comprehensive surgical staging with peritoneal washing cytology, omentectomy, peritoneal biopsy, and pelvic plus para-aortic lymphadenectomy, is performed. After surgical staging, adjuvant chemotherapy with a combination of paclitaxel and carboplatin is performed in advanced disease. However, the prognosis of patients with malignant transformation of MCTO is worse than that of patients with common epithelial ovarian cancer ^[@B4]^. Prognostic factors have been reported in patients with malignant transformation of MCTO. Age \> 45 or 55 years, advanced staging, larger tumor, high cancer grade, absence of hysterectomy, presence of residual tumor lesions, absence of adjuvant chemotherapy, and non-platinum-based chemotherapy ^[@B13],\ [@B16],\ [@B31],\ [@B32]^ are poor prognostic factors. Lymphadenectomy is not a major prognostic factor in patients with malignant transformation of MCTO ^[@B13],\ [@B31]^. In this case, however, a strict follow-up for stage IA ovarian cancer was conducted, and tumor recurrence in retroperitoneal lymph nodes developed 3 months after the initial surgery. Hurwitz *et al.* reported that secondary reduction surgery was effective in two patients with recurrence of malignant transformation of MCTO ^[@B33]^. In this case, the patient underwent adjuvant chemotherapy following radical surgery without residual lesions, and no recurrence was observed for 2 years after treatment. Secondary cytoreductive surgery might be considered in selected patients with recurrence of malignant transformation of MCTO.

Although ovarian tumor torsion requires emergency surgery, when physicians encounter large ovarian tumor torsion cases, preoperative examinations should be performed, keeping the possibility of malignancy in mind.
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